CRNX
Crinetics Pharmaceuticals
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- Crinetics Pharmaceuticals received European Commission approval of PALSONIFY for treating acromegaly in adultsApr 28, 2026
- Crinetics initiated Phase 2/3 pediatric trial of atumelnant in congenital adrenal hyperplasiaJan 23, 2026
- Crinetics reports strong PALSONIFY launch and positive Phase 2 atumelnant data showing lower androstenedione and reduced glucocorticoid doses in congenital adrenal hyperplasiaJan 5, 2026
- Crinetics to provide PALSONIFY business update and announce topline results from fourth cohort of Phase 2 atumelnant trial in congenital adrenal hyperplasiaJan 5, 2026
- Crinetics announced first patient dosed in Phase 1/2 trial evaluating CRN09682 for neuroendocrine tumors and somatostatin receptor 2-expressing tumorsDec 3, 2025